Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter Alerted FDA To Problem Before Receiving Warning Letter, Firm Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The letter details problems related to Baxter's use of albumin in the manufacturing of its Isolex 300i Magnetic Cell Selection System, a device/biologic regulated as a Class III device.

You may also be interested in...



First-Ever Stem Cell GMP Warning Letter Cites IntelliCell

FDA finds the company failed to establish procedures for a range of GMP basics, which is a problem because according to the agency the IntelliCell adipose tissue-derived stem cells are both a drug and a biologic product.

Baxter Receives Warning Letter For Fibrin Sealant Promotional Materials

An FDA warning letter charges that promotional materials for Baxter's Tisseel fibrin sealant constitute misbranding of the product

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel